title: [Non-alcoholic fatty liver disease (NAFLD)].
abstract: Non-alcoholic fatty liver disease is the most common chronic liver disease in Europe and in the USA with rising prevalence. Patients with a metabolic syndrome (diabetes mellitus, obesity, dyslipidemia) are patients at risk with the highest prevalence for NAFLD. Progression from a non-alcoholic fatty liver (NAFL) to a non-alcoholic steatohepatitis (NASH) occurs in 5-20% of patients with the potential to develop a liver fibrosis/cirrhosis. NASH patients and NAFLD patients with higher fibrosis should be identified because they are at risk of a higher mortality. A specific treatment for NASH is not available at the moment. Therefore, the treatment of risk factors and metabolic syndrome has high priority.
authors.affiliation: Schwerpunkt Hepatologie, Medizinische Klinik II, Universitätsklinik Würzburg.
authors.forename: Monika
authors.initials: M
authors.lastname: Rau
authors.affiliation: Schwerpunkt Hepatologie, Medizinische Klinik II, Universitätsklinik Würzburg.
authors.forename: Johannes
authors.initials: J
authors.lastname: Weiss
authors.affiliation: Schwerpunkt Hepatologie, Medizinische Klinik II, Universitätsklinik Würzburg.
authors.forename: Andreas
authors.initials: A
authors.lastname: Geier
mesh_terms: D015897:Comorbidity; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D018450:Disease Progression; D050171:Dyslipidemias / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D038622:Internationality; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D065626:Non-alcoholic Fatty Liver Disease / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D009765:Obesity / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D015995:Prevalence; D012307:Risk Factors